<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268903</url>
  </required_header>
  <id_info>
    <org_study_id>AOM 130519</org_study_id>
    <nct_id>NCT02268903</nct_id>
  </id_info>
  <brief_title>Diuretic Versus Placebo in Pulmonary Embolism</brief_title>
  <acronym>DiPER</acronym>
  <official_title>Diuretic Versus Placebo in Pulmonary Embolism With Right Ventricular Enlargement: a Double-blind Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Embolism (PE) is a frequent and severe disease with an annual incidence of about
      75000 cases in France and a short-term mortality rate of about 10%. Death is usually related
      to an acute right ventricular (RV) failure due to the increase in right ventricular
      afterload. Treatment of PE with RV failure consists in fluid expansion and thrombolysis in
      case of shock. However several studies suggest that fluid expansion may worsen acute RV
      failure by increasing RV dilatation and ischemia and left ventricular compression by RV
      dilatation. Thus, current guidelines regarding PE treatment remain unclear about the use of
      fluid expansion. In a preliminary study published by our group, we showed that diuretic
      treatment in the setting of PE with RV dilatation is safe and is associated with an increase
      in urine output, a decrease in heart rate and an increase in SpO2 in normotensive patients
      with oliguria. This may be related to the decrease of ventricular interdependence and
      enhancement of both LV and RV function.

      The main objective of the study is to evaluate the 24-hours clinical benefit of furosemide in
      patients referred for acute PE with RV dilatation compared to placebo. The combination of
      urine output and sPESI clinical parameters reflects hemodynamic status. It is relevant as it
      indicates the disappearance of pre-shock symptoms and is therefore associated with a lower
      event risk. Thus, it allows early discharge of the patients from the intensive care unit.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary end point will be a combined clinical criterion, to reach the primary endpoint, patients have to meet all the following criteria: - Urine output&gt; 0.5ml/kg/h - Normalization of clinical parameters of simplified PESI score</measure>
    <time_frame>24 hours</time_frame>
    <description>Normalization of clinical parameters of simplified PESI score :
Heart Rate&lt;110/min
Systolic blood pressure≥100mmHg
Arterial oxyhemoglobin level&gt;90% on room air or after 5 minutes of oxygen withdrawal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patients have to meet all the four following criteria: - Urine output&gt; 0.5ml/kg/h over 24 hours - Normalization of clinical parameters of simplified PESI score - Urine output</measure>
    <time_frame>48 hours</time_frame>
    <description>Normalization of clinical parameters of simplified PESI score :
Heart Rate&lt;110/min
Systolic blood pressure≥100mmHg
Arterial oxyhemoglobin level&gt;90% on room air or after 5 minutes of oxygen withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Composite criteria including death, need for catecholamine, cardiac arrest and mechanical ventilation during hospitalization and at 1 month from inclusion - NYHA score</measure>
    <time_frame>In hospital and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>o RV/LV ratio and decrease from baseline o Systolic pulmonary pressure and decrease from baseline o Tricuspid annular plane systolic expansion (TAPSE) at o Tricuspid annular plane systolic expansion (TAPSE) variation from baseline</measure>
    <time_frame>24 hours abd 1 month</time_frame>
    <description>RV/LV ratio (diameters and surfaces)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- NT-proBNP or BNP decrease at 24hours - Creatinin and liver enzymes variations at 24hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Pulmonary Embolism With Right Ventricle Enlargement</condition>
  <arm_group>
    <arm_group_label>Diuretics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diuretics : Furosemide</intervention_name>
    <description>Furosemide 80mg in one single direct intra venous injection</description>
    <arm_group_label>Diuretics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in one single direct intra venous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged 18 years and over with

          1. Symptomatic acute pulmonary embolism with first clinical symptoms within 15 days, and
             objectively confirmed by CT scan

          2. RV dysfunction (≥1 criterion) confirmed by elevated BNP value or echocardiography or
             spiral computed tomography of the chest:

               -  Echocardiography

                  o Right/Left ventricular end diastolic diameter &gt; 1(apical or subcostal 4-chamber
                  view)

               -  Computed tomography

                  o Right/Left short-axis diameter ratio&gt;0.9 (transverse plane)

               -  Positive Nt-proBNP (&gt;600) or BNP&gt;200 pg/mL

          3. One abnormal following PESI criteria

               -  Heart Rate&gt;110/min

               -  Systolic blood pressure&lt;100mmHg

               -  Arterial oxyhemoglobin level&lt;90% on room air or after 5 minutes of oxygen
                  withdrawal.

        Exclusion Criteria:

          -  Cardiogenic shock requiring thrombolysis

          -  Previous significant left ventricular insufficiency (LVEF&lt;45%)

          -  Systolic blood pressure&lt;90mmHg at admission

          -  Age ≤ 18 years

          -  Pregnancy

          -  No health insurance

          -  Patients deprived of liberty or under legal protection

          -  Creatinin clearance &lt;30mL/min/m²

          -  hypersensibility to furosemide or its excipients

          -  functional renal insufficiency

          -  Hepatic encephalopathy

          -  Urinary tracks obstruction

          -  Hypovolemia or dehydration.

          -  Sever hypokalemia (K+ &lt; 3mmol/L)

          -  Severe hyponatremia (Na+ &lt; 125mmol/L)

          -  Ongoing hepatitis and hepatic insufficiency severe in patients with renal
             insufficiency or dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc DUBOIS-RANDE, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Luc DUBOIS-RANDE, PU-PH</last_name>
    <phone>(0)1 49 81 36 02</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-luc.duboisrande@hmn.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romain GALLET, CCA</last_name>
    <phone>(0)1 49 81 36 02</phone>
    <phone_ext>+33</phone_ext>
    <email>romain.gallet@yahoo.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc DUBOIS-RANDE, PU-PH</last_name>
      <phone>(0)1 49 81 36 02</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-luc.duboisrande@hmn.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Dalila SELMANE, CRA</last_name>
      <phone>(0)1 49 81 33 86</phone>
      <phone_ext>+33</phone_ext>
      <email>dalila.selmane@hmn.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pascal LIM, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 2002 Mar;121(3):877-905. Review.</citation>
    <PMID>11888976</PMID>
  </reference>
  <reference>
    <citation>Lee FA. Hemodynamics of the right ventricle in normal and disease states. Cardiol Clin. 1992 Feb;10(1):59-67. Review.</citation>
    <PMID>1739960</PMID>
  </reference>
  <reference>
    <citation>Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008 Sep;29(18):2276-315. doi: 10.1093/eurheartj/ehn310. Epub 2008 Aug 30.</citation>
    <PMID>18757870</PMID>
  </reference>
  <reference>
    <citation>Perlroth DJ, Sanders GD, Gould MK. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Arch Intern Med. 2007 Jan 8;167(1):74-80.</citation>
    <PMID>17210881</PMID>
  </reference>
  <reference>
    <citation>Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Come PC, Lee RT, Parker JA, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993 Feb 27;341(8844):507-11.</citation>
    <PMID>8094768</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Right Ventricle failure</keyword>
  <keyword>Diuretics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

